Related Experiment Videos
Wolff-Parkinson-White syndrome and sudden cardiac death
Insights
Sudden cardiac death (SCD) in asymptomatic patients with Wolff-Parkinson-White (WPW) syndrome is rare but possible. More research is needed to identify at-risk individuals and determine appropriate treatment for WPW syndrome.
Area of Science:
- Cardiology
- Electrophysiology
- Sudden Cardiac Death
Background:
- Sudden cardiac death (SCD) can occur in individuals without prior heart disease.
- Accessory pathways, as seen in Wolff-Parkinson-White (WPW) syndrome, may contribute to fatal arrhythmias.
- The natural history of asymptomatic WPW syndrome is poorly understood.
Purpose of the Study:
- To review the potential role of accessory pathways in SCD.
- To discuss the controversy surrounding testing and treatment for asymptomatic WPW patients.
- To highlight the need for further research into the natural history of WPW syndrome.
Main Methods:
- Literature review and synthesis of existing knowledge on WPW syndrome and SCD.
- Discussion of electrophysiologic study findings and case reports.
- Analysis of the current controversies in managing asymptomatic WPW patients.
Main Results:
- SCD in asymptomatic WPW patients is likely rare.
- The pathway from atrioventricular reciprocating tachycardia (AVRT) to ventricular fibrillation via an accessory pathway is a potential mechanism for SCD.
- There is a lack of data to guide risk stratification and treatment decisions for asymptomatic WPW syndrome.
Conclusions:
- Identifying asymptomatic WPW patients at risk for SCD is challenging due to limited data.
- Long-term prospective studies are essential to clarify which patients require intervention.
- Current management strategies for asymptomatic WPW syndrome remain controversial.
Abstract:
Every year, individuals with no history of heart disease succumb to sudden cardiac death (SCD). Pathologic examination of the hearts usually reveals various forms of heart disease as hypertrophic cardiomyopathy or coronary artery disease. In other cases, however, there is no obvious structural heart disease, and it is possible that some of these individuals died because of a cardiac arrhythmia involving an accessory pathway. If this were the case, the most likely scenario would be onset of atrioventricular reciprocating tachycardia (AVRT), degeneration of the AVRT into atrial fibrillation with a rapid ventricular response over the accessory pathway, and subsequent death caused by the development of ventricular fibrillation. Although these events have been documented, albeit rarely, during intracardiac electrophysiologic studies, in reality very little is known about the natural history of asymptomatic and untreated patients with Wolff-Parkinson-White (WPW) syndrome. In fact, SCD in a previously asymptomatic patient with WPW syndrome is probably relatively rare. Whether asymptomatic WPW patients should undergo electrophysiologic or pharmacologic testing to determine their 'potential' to develop serious cardiac arrhythmias is controversial. The present paucity of data concerning the natural history of WPW syndrome in asymptomatic patients militates against successful identification of those patients who are at risk for sudden death. Long-term prospective studies are necessary to clarify which asymptomatic patients with WPW syndrome require treatment.